Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab plus apatinib in progressive cholangiocarcinoma
ChiCTR2000037933Phase 2Recruiting
- Sponsor
- Hunan Provincial People's Hospital
- Start
- Aug 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab and Rivoceranib in cholangiocarcinoma (CCA), sponsored by Hunan Provincial People's Hospital. Primary endpoint: 6-month overall survival. Started Aug 2020; status: recruiting.
02
Drugs
camrelizumabRivoceranib
03
Conditions
cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on ChiCTR2000037933.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000037933.